Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Achieve Life Sciences (Nasdaq: ACHV) appointed Benjamin Halladay as Chief Financial Officer, effective October 5, 2026, succeeding Mark Oki.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Achieve Life Sciences (Nasdaq: ACHV) appointed Benjamin Halladay as Chief Financial Officer, effective October 5, 2026, succeeding Mark Oki. Halladay will oversee financial strategy, accounting, investor relations, information technology and other administrative functions. Oki will step down on the same date, having served through Achieve’s Phase 3 program and New Drug Application submission.
Halladay served as CFO of Esperion Therapeutics from November 2022 until July 2026 and brings more than 15 years of financial management experience across commercial and launch environments. His earlier roles included work on Lipitor and Chantix at Pfizer and a position at National Oilwell Varco. Achieve said his public-company finance and operating experience fits its preparations for potential commercialization of cytisinicline, its treatment in development for nicotine dependence.
Key Terms
new drug application (nda) regulatory
breakthrough therapy designation regulatory
open-label medical
nicotinic acetylcholine receptor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline
SEATTLE and VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Benjamin Halladay, CPA, as Chief Financial Officer, effective October 5, 2026. He will be responsible for the Company’s financial strategy, accounting, investor relations, information technology, and other key administrative functions.
Mr. Halladay joins Achieve from Esperion Therapeutics, a commercial-stage pharmaceutical company with more than
“Ben has helped scale a commercial pharma organization and expand its portfolio through business development within its existing capital structure,” said Andrew D. Goldberg, MD, Chief Executive Officer, Achieve. “He has run the finance function as a public company CFO, and began his biopharma finance career in large-cap pharma. As we move toward potential commercialization of cytisinicline, that combination of capital efficiency and operating experience is exactly what this stage demands.”
“The discipline that determines how a launch goes is put in place long before the first prescription is written,” said Mr. Halladay. “That is the work I’m excited to do. Achieve is developing a medicine that could change what quitting looks like for millions of people, and my job is to build the financial and operating foundation that supports it, on schedule and on plan.”
Mr. Halladay holds an MBA from Fordham University and a BA from Syracuse University, and is a Certified Public Accountant (inactive).
Mark Oki will step down as Chief Financial Officer of Achieve, effective October 5, 2026, and Mr. Halladay succeeds him in the role. Mr. Oki served as Chief Financial Officer through Achieve’s Phase 3 program and NDA submission, and the Company thanks him for his contributions.
ABOUT ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
ABOUT CYTISINICLINE
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Tobacco use is currently the leading cause of preventable death, responsible for more than seven million deaths worldwide and nearly half a million deaths in the United States annually.²,³
In addition, there are nearly 18 million adults in the United States who use e-cigarettes, also known as vaping.¹ In 2025, approximately 1.4 million middle and high school students in the United States reported using e-cigarettes.⁴ There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. FDA has awarded Achieve the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine dependence for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements regarding the timing and outcome of Achieve’s planned NDA resubmission for cytisinicline, the timing of any FDA decision, the potential benefits of cytisinicline, the potential market for cytisinicline, the Company’s commercialization plans and readiness, and the anticipated benefits of new executive leadership. Achieve may not achieve its plans, projections, or other expectations and may not be able to successfully complete its NDA resubmission or obtain regulatory approval for cytisinicline on the anticipated timeline or at all. These statements are based on management’s current expectations and beliefs and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those detailed in Achieve’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Achieve undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
CONTACT
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510
REFERENCES
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.
²World Health Organization. WHO Report on the Global Tobacco Epidemic, 2025. Geneva: World Health Organization; 2025.
³U.S. Department of Health and Human Services. The Health Consequences of Smoking, 50 Years of Progress. A Report of the Surgeon General. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
⁴Eunice Park-Lee, Lauren M Dutra, Hannah Cowan, et al. Tobacco Product Use Among Middle and High School Students in the United States: National Youth Tobacco Survey, 2025, Nicotine & Tobacco Research, 2026; ntag116, doi.org/10.1093/ntr/ntag116.
